Lung Cancer

Cancer Screening: Theory and Practice

Volumn , Issue , 2021, Pages 327-377

  Black, William C ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85130920079     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429179587-16     Document Type: Chapter

References (127)

1. United States Preventive Services Task Force. Screening for lung cancer. In: Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins, 1996:135-139.
2. Parker S L, Bolden S, Tong T, Wingo W A. Cancer statistics, 1996. CA Cancer J Clin 1996; 46:5-27.
3. Czaja R, McFall S L, Warnecke R B, Ford L, Kaluzny A D. Preferences of community physicians for cancer screening guidelines. Ann Intern Med 1994; 120:602-608.
4. Ries LAG, Kosary C L, Hankey B F, Miller B A, Harms A, Edwards B K (eds). SEER Cancer Statistics Review, 1973-1994 [NIH Pub. No. 97-2789]. Bethesda, MD: National Cancer Institute, 1997:285.
5. Ernster V L. The epidemiology of lung cancer in women. Ann Epidemiol 1994; 4:102-110.
6. Shopland D R. Effect of smoking on the incidence and mortality of lung cancer. In: Johnson B E, Johnson D H, eds. Lung Cancer. New York: Wiley-Liss, 1995: 1-14.
7. Halpern M T, Gillespie B W, Warner K E. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457-464.
8. Tong L, Spitz M R, Fueger J J, Amos C A. Lung carcinoma in former smokers. Cancer 1996; 78:1004-1010.
9. Tobacco use and usual source of cigarettes among high school students-United States, 1995. MMWR Morb Mortal Wkly Rep 1996; 45:413-418.
10. Kreyberg L. International histological classification of tumours. In: Histological Typing of Lung Tumours. Geneva: World Health Organization, 1981.
11. Devesa S S, Shaw G L, Blot W J. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991; 1:29-34.
12. Wynder E L, Muscat J E. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995; 103(suppl 8): 143-148.
13. Campobasso O, Andrion A, Ribotta M, Ronco G. The value of the 1981 WHO histological classification in inter-observer reproducibility and changing pattern of lung cancer. Int J Cancer 1993; 53:205-208.
14. Ginsberg R J, Vokes E E, Raben A. Non-small lung cancer. In: Devita V T, Hell-man S, Rosenberg S A, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997: 858-911.
15. Linnoila RI, Aisner S C. Pathology of lung cancer: an exercise in classification. In: Johnson B E, Johnson D H, eds. Lung cancer. New York: Wiley-Liss, 1995: 73-95.
16. Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histolo-pathological classification of lung cancer. Am Rev Respir Dis 1970; 101:671-684.
17. Keehn R, Auerbach O, Nambu S, et al. Reproducibility of major diagnoses in a binational study of lung cancer in uranium miners and atomic bomb survivors. Am J Clin Pathol 1994; 101:478-482.
18. U.S. Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. [DHHS Publication No. (CDC) 89-8411]. Rockville, MD: U.S. Department of Health and Human Services, 1989.
19. Shopland D R, Eyre H J, Pechacek T F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst 1991; 83:1142-1148.
20. Blot W J, Fraumeni J F. Cancers of the lung and pleura. In: Schottenfeld D, Frau-meni J F, eds. Cancer epidemiology and prevention. New York: Oxford University Press, 1996:637-665.
21. Chow W H, Schuman L M, McLaughlin J K, et al. A cohort study of tobacco use, diet, occupation, and lung cancer mortality. Cancer Causes Control 1992; 3:247-254.
22. Morabia A, Wynder E L. Cigarette smoking and lung cancer cell types. Cancer 1991; 68:2074-2078.
23. Morabia A, Wynder E L. Relation of bronchioloalveolar carcinoma to tobacco. BMJ 1992; 304:541-543.
24. National Research Council. Committee on the Biological Effects of Ionizing Radiation. Health effects of exposure to low levels of ionizing radiation (BEIR V). Washington, DC: National Academy Press, 1990.
25. Lubin J H, Boice J D J, Edling C, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J Natl Cancer Inst 1995; 87:817-827.
26. Lubin J H, Boice J D J. Lung cancer risk from residential radon: meta-analysis from eight epidemiologic studies. J Natl Cancer Inst 1997; 89:49-57.
27. Samet J M. Indoor radon and lung cancer: risky or not?-all over again. J Natl Cancer Inst 1997; 89:4-6.
28. Cohen A J, Pope CAr. Lung cancer and air pollution. Environ Health Perspect 1995; 103(suppl 8): 219-224.
29. Rigas J R, Miller V A, Zhang Z F, et al. Metabolic phenotypes of retinoic acid and the risk of lung cancer. Cancer Res 1996; 56:2692-2696.
30. Spitz M R, Hsu T C. Mutagen sensitivity as a marker of cancer risk. Cancer Detect Prev 1994; 18:299-303.
31. Spitz M R, Hsu T C, Wu X, Fueger J J, Amos C I, Roth J A. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 1995; 4:99-103.
32. Strom S S, Wu S, Sigurdson A J, et al. Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans. J Natl Cancer Inst Monogr 1995; 18:29-33.
33. Ziegler R G, Mayne S T, Swanson C A. Nutrition and lung cancer. Cancer Causes Control 1996; 7:157-177.
34. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
35. Omenn G S, Goodman G E, Thornquist M D, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-1155.
36. Mayne S T, Handelman G J, Beecher G. Beta carotene and lung cancer promotion in heavy smokers-a plausible relationship? J Natl Cancer Inst 1996; 88:1513-1515.
37. Auerbach O, Garfinkle L, Parks V R. Scar carcinoma of the lung: increase over a 21-year period. Cancer 1979; 43:636-642.
38. Fraser R S, Pare J A P, Fraser R G, Pare P D. Neoplastic diseases of the lungs. In: Synopsis of Diseases of the Chest. Philadelphia: W B Saunders, 1994: 445-538.
39. Muhn J R, Miller W E, Fontana R S, Sanderson D R, Uhlenhopp M A. Lung cancer detected during a screening program using four-month chest radiographs. Radiology 1983; 148:609-615.
40. Soda H, Tomita H, Kohno S, et al. Limitation of annual screening chest radiography for the diagnosis of lung cancer. A retrospective study. Cancer 1993; 72:2341-2346.
41. Hakama M, Holli K, Visakorpi T, Pekola M, Kallioniemi O. Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. Int J Cancer 1996; 66:6-10.
42. Cole P, Morrison A S. Basic issues in population screening for patients. J Natl Cancer Inst 1980; 64:1263-1272.
43. Yankelevitz D F, Henschke C I. Does 2-year stability imply that pulmonary nodules are benign? Am J Roentgenol 1997; 168:325-328.
44. Armstrong P. Basic patterns in lung disease. In: Armstrong P, Wilson A G, Dee P, Hansell D M, eds. Imaging of Diseases of the Chest. 2d ed. St. Louis: Mosby, 1995:58-124.
45. Armstrong P. Neoplasms of the lungs, airways, and pleura. In: Armstrong P, Wilson A G, Dee P, Hansell D M, eds. Imaging of Diseases of the Chest. 2d ed. St. Louis: Mosby, 1995:272-368.
46. Swensen S J, Brown L R, Colby T V, Weaver A L, Midthun D E. Lung nodule enhancement at CT: prospective findings. Radiology 1996; 201:447-455.
47. Gurney J W. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. Radiology 1993; 186:405-413.
48. Gurney J W, Lyddon D M, McKay J A. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part II. Application. Radiology 1993; 186:415-422.
49. Mountain C F. Revisions in the International System for Staging Lung Cancer [see comments]. Chest 1997; 111(6): 1710-1717.
50. Idhe D C, Pass H I, Glatstein E J. Small cell lung cancer. In: Devita V T, Hellman S, Rosenberg S A, ed. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:911-949.
51. Black W C, Armstrong P, Daniels T M. Cost-effectiveness of CT in T1N0M0 lung cancer. Radiology 1988; 167:373-378.
52. Conces D J, Klink J F, Tarver R D, Moak G D. T1N0M0 lung cancer: evaluation with CT. Radiology 1989; 170:643-646.
53. Becker G L, Whitlock W L, Schaefer P S, Tenholder M F. The impact of thoracic computed tomography in clinically staged Tl, NO, MO chest lesions. Arch Intern Med 1990; 150:557-559.
54. Duncan K A, Gomersall L N, Weir J. Computed tomography of the chest in TINoMo non-small cell bronchial carcinoma. Br J Radiol 1993; 66:20-22.
55. Michel F, Soler M, Imhof E, Perruchoud A. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991; 46:469-473.
56. Hatter J, Kohman L J, Mosca R S, Graziano S L, Veit L J, Coleman M. Preoperative evaluation of stage I and stage II non-small cell lung cancer. Ann Thorac Surg 1994; 58:1738-1741.
57. Silvestri G A, Littenberg B, Colice G L. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med 1995; 152:225-230.
58. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 1995; 108:1264-1271.
59. Mountain C F. A new international staging system for lung cancer. Chest 1986; 89(suppl):225-233.
60. Prorok P C, Hankey B F, Bundy B M. Concepts and problems in the evaluation of screening programs. J Chronic Dis 1981; 34:159-171.
61. Black W C, Welch H G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328:1237-1243.
62. Kramer B S, Gohagan J, Prorok PC. NIH Consensus 1994: screening. Gynecol Oncol 1994; 55(3 pt 2):S20-S21.
63. National Council on Radiation Protection and Measurements (NRCP). Ionizing radiation exposures of the population of the United States. Report No. 93. Washington, DC: National Council on Radiation Protection and Measurements, 1987.
64. American College of Radiology Standards. The performance of adult chest radiography. 1995:41-45.
65. Berlin N I, Buncher C R, Fontana R S, Frost J K, Melamed M R. The National Cancer Institute Cooperative Early Lung Cancer Detection Program: results of the initial screen (prevalence). Am Rev Respir Dis 1984; 130:545-549.
66. Stitik F P, Tockman M S, Khouri N G. Chest radiology. In: Miller A B, ed. Screening for cancer. Orlando, FL: Academic Press, 1985: 163-191.
67. Woodring J H. Pitfalls in the radiologic diagnosis of lung cancer. Am J Roentgenol 1990; 154:1165-1175.
68. Austin J H, Romney B M, Goldsmith L S. Missed bronchogenic carcinoma: radiographic findings in 27 patients with a potentially resectable lesion evident in retrospect. Radiology 1992; 182:115-122.
69. Kundel H L, Nodine C F, Carmody D. Visual scanning, pattern recognition, and decision making in pulmonary nodule detection. Invest Radiol 1978; 13:175-181.
70. Morrison A S. Early detection: sensitivity and lead time. In: Screening in Chronic Disease. 2d ed. New York: Oxford University Press, 1992: 43-73.
71. Sobue T, Suzuki T, Matsuda M, Horai T, Kajita A, Kuriyama K. Sensitivity and specificity of lung cancer screening in Osaka, Japan. Jpn J Cancer Res 1991; 82:1069-1076.
72. Melamed M R, Flehinger B J, Zaman M B, Heelan R T, Perchick W A, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering Study in New York. Chest 1984; 86:44-53.
73. Fontana R S, Sanderson D R, Woolner L B, et al. Screening for lung cancer. Cancer 1991; 67(suppl): 1155-1164.
74. Flehinger B J, Melamed M R. Current status of screening for lung cancer. Chest Surg Clin North Am 1994; 4:1-14.
75. Steele J D. The solitary pulmonary nodule: report of a cooperative study of asymptomatic solitary pulmonary nodules in males. J Thorac Cardiovasc Surg 1963; 46:21-39.
76. Early lung cancer detection. Summary and conclusions. Am Rev Respir Dis 1984; 130:565-567.
77. Bailar J C. Screening for lung cancer: where are we now? Am Rev Respir Dis 1984; 130:541-542.
78. Mulshine J L, Linnoila R I, Jensen S M, et al. Rational targets for the early detection of lung cancer. Monogr Natl Cancer Inst 1992; 13:183-190.
79. Weiss W. Survivorship among men with bronchogenic carcinoma: three studies in populations screened every six months. Arch Environ Health 1971; 22:168-173.
80. Boucot K R, Weiss W. Is curable lung cancer detected by semiannual screening? JAMA 1973; 224: 1361-1365.
81. Lilienfield A, Archer PG, Burnett C H, et al. An evaluation of radiologic and cytologic screening for early detection of lung cancer: a cooperative pilot study of the American Cancer Study and the Veterans Administration. Cancer Res 1966; 26:2083-2121.
82. Nash F A, Morgan J M, Tomkins J G South London lung cancer study. BMJ 1968; 2:715-721.
83. Black WC, Welch HG. Screening for disease. Am J Roentgenol 1997; 168:3-11.
84. Brett G Z. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23:414-420.
85. Brett G Z. Earlier diagnosis and survival in lung cancer. BMJ 1969; 4:260-262.
86. Fontana R S, Sanderson D R, Taylor W F, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 1984; 130:561-565.
87. Sanderson D R. Lung cancer screening: the Mayo study. Chest 1986; 89(suppl): 324.
88. Flehinger B J, Melamed M R, Zaman M B, Heelan R T, Perchick W A, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering Study. Am Rev Respir Dis 1984; 130:555-560.
89. Martini N. Results of the Memorial Sloan-Kettering study in screening for lung cancer. 1986; 89(suppl):325.
90. Frost J K, Ball W C, Levin M L, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130:549-554.
91. Tockman MS. Lung cancer screening: the Johns Hopkins study. Chest 1986; 89(suppl):324.
92. Wilde J. A 10-year follow-up of semi-annual screening for early lung cancer in the Erfurt County (GDR). Eur Respir J 1989; 2:656-662.
93. Kubic A, Polak J. Lung cancer detection. Results of a randomised prospective study in Czechoslovakia. 1986; 57:2427-2437.
94. Kubic A, Parkin D M, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45:26-33.
95. Kramer B S, Gohagan J, Prorok P C, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71:589-593.
96. National Cancer Institute. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Manual of Operations and Procedures. Rockville, MD: Westat, Inc, 1993.
97. Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer reexamined: a reinterpretation of the Mayo Lung Project randomized trial on lung cancer screening. Chest 1993; 103(suppl):337-341.
98. Strauss. Chest X-ray screening for lung cancer (letter). Chest 1995; 108:1770-1772.
99. Strauss G M, Gleason R E, Sugarbaker D J. Screening for lung cancer. Another look; a different view [see comments]. Chest 1997; 111:754-768.
100. Parkin D M, Pisani P. Lung cancer screening (letter). Chest 1994; 106:977.
101. Chan C K, Wells C K, McFarlane M J, Feinstein A R. More lung cancer but better survival: implications of secular trends in “necropsy surprise” rates. Chest 1989; 96:291-296.
102. Eddy D. Screening for lung cancer. Ann Intern Med 1989; 111:232-237.
103. Weiss W. Chest X-ray screening for lung cancer (letter). Chest 1995; 108:1770.
104. Morrison A S. The natural history of disease in relation to measures of disease frequency. In: Screening in Chronic Disease. 2d ed. New York: Oxford University Press, 1992:25-42.
105. Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. Survival for clinical stage I lung cancer not surgically treated. Comparison between screen-detected and symptom-detected cases. The Japanese Lung Cancer Screening Research Group. Cancer 1992;69:685-692.
106. Lachin J M. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 1981;2:93-113.
107. Weiss N S, McKnight B, Stevens N G. Approaches to the analysis of case-control studies of the efficacy of screening for cancer. Am J Epidemiol 1992; 135:817-823.
108. Connor R J, Prorok P C, Weed D L. The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol 1991;44:1215-1221.
109. Sasco A J, Day N E, Walter S D. Case-control studies for the evaluation of screening. J Chron Dis 1986; 39:399-405.
110. Ebeling K, Nischan P. Screening for lung cancer-results from a case control study. Int J Cancer 1987; 40:141-144.
111. Berndt R, Nischan P, Ebeling K. Screening for lung cancer in the middle-aged. Int J Cancer 1990; 45:229-230.
112. Morrison A S. Assessing the value of early treatment: non-experimental studies. In: Screening in Chronic Disease. 2d ed. New York: Oxford University Press, 1992:98-128.
113. Sobue T, Suzuki T, Naruke T, Group J L-C-S R. A case-control study for evaluating lung-cancer screening in Japan. Int J Cancer 1992; 50:230-237.
114. Hennekens C H, Buring J E. Case-control studies. In: Epidemiology in Medicine. Boston: Little, Brown, 1987:132-152.
115. Wardle J, Pope R. The psychological costs of screening for cancer. J Psychosom Res 1992; 36:609-624.
116. Reich J M. More on lung cancer screening (letter). Chest 1995; 108:294.
117. Riley G F, Potosky A L, Lubitz J D, Kessler L G. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33:828-841.
118. Heiken J P, Brink J A, Vannier M W. Spiral (helical) CT. Radiology 1993; 189:647-656.
119. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201:798-802.
120. Rubin G D, Beaulieu C F, Argiro V, et al. Perspective volume rendering of CT and MR images: applications for endoscopic imaging. Radiology 1996; 199:321-330.
121. Vining D J, Liu K, Choplin R H, Haponik E F. Virtual bronchoscopy. Relationships of virtual reality endobronchial simulations to actual bronchoscopic findings. Chest 1996; 109:549-553.
122. Mulshine J L, Scott F. Molecular markers in early cancer detection. New screening tools. Chest 1995; 107(suppl):280-286.
123. Tockman M S. Monoclonal antibody detection of premalignant lesions of the lung. In: Fortner J G S P, ed. Accomplishments in Cancer Research, 1995. Philadelphia: Lippincott-Raven, 1996:169-177.
124. Wagner H, Ruckdeschel J C. Lung Cancer. In: Reintgen D S, Clark RA, eds. Cancer Screening. St. Louis: Mosby, 1996:118-149.
125. Kaplan R M. Quality of life assessment for cost/utility studies in cancer. Cancer Treat Rev 1993; 19(suppl A): 85-96.
126. Nease R F J, Tsai R, Hynes L M, Littenberg B. Automated utility assessment of global health. Qual Life Res 1996; 5:175-182.
127. Russell L B, Gold M R, Siegel J E, Daniels N, Weinstein M C. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1172-1177.